Quest PharmaTech Inc.
Quest PharmaTech Inc.
Your view on QPTFF
Overview
What the company does, where it operates, and who runs it.
About Quest PharmaTech Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Ragupathy Madiyalakan
- Headquarters
- 8123 Roper Road NW, Edmonton, AB, CA
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Ragupathy Madiyalakan
- Headquarters
- 8123 Roper Road NW, Edmonton, AB, CA
Quest PharmaTech Inc., a pharmaceutical company, develops antibody based immunotherapeutic products for cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications.
The company also offers Oregovomab, an anti-CA-125 antibody, which has completed Phase II clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer.
Further, the company develops products by using proprietary transdermal delivery technologies for dermatology and wound healing applications; skin penetrating active molecules for cosmetic and pharmaceutical use; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Quest PharmaTech Inc., and the rating behind it. QPTFF last traded at $0.01, 1.0× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Quest PharmaTech Inc.. Starting points for Quest PharmaTech Inc.: P/E 1.0, EPS $0.03, beta -0.41 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Quest PharmaTech Inc.. Quest PharmaTech Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Quest PharmaTech Inc.. Trailing twelve-month EPS for Quest PharmaTech Inc. stands at $0.03. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Quest PharmaTech Inc.. Quest PharmaTech Inc. has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Quest PharmaTech Inc. valued side by side against its closest peers. Quest PharmaTech Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Quest PharmaTech Inc., and how their positions are changing. At a $2.2M market value, institutional positions materially move Quest PharmaTech Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Quest PharmaTech Inc. executives and directors. Shares of Quest PharmaTech Inc. have traded between $0.01 and $0.04 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Quest PharmaTech Inc.. Quest PharmaTech Inc. is a $2.2M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Quest PharmaTech Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Quest PharmaTech Inc.. Coverage tracks Quest PharmaTech Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.